Wockhardt announced that U. S. Food and Drug Administration ('USFDA') has carriedout inspection of Bioequivalence Centre located at R&D Centre, Aurangabad during whichBioequivalence studies of Tamsulosin 0.4mg capsules and Metoprolol Tartrate 200mg ER tabletswere audited. At the end of inspection, there was Nil observation (i.e. zero 483 observation),signifying that best practices were followed, in compliance to applicable regulations. This outcomewould lead approvals of ANDAs in pipeline for which Bioequivalence studies are being or will bedone in the said Centre.